TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 38
- +2 vs. Q3 2024
- Portfolio value
- $1.02B
- −$157.0M (−13.3%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 3,670,206 | $105.3M | 10.3% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,650,150 | $62.4M | 6.1% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 2,452,138 | $56.4M | 5.5% | +25,000+1.0% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 6,964,375 | $54.3M | 5.3% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,890,816 | $48.4M | 4.7% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 5,319,148 | $45.4M | 4.4% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 2,801,763 | $44.9M | 4.4% | +2,801,763 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 6,056,596 | $44.3M | 4.3% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,362,205 | $38.0M | 3.7% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 10,736,000 | $33.2M | 3.2% | +10,736,000 | New | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,501,624 | $32.7M | 3.2% | +1,501,624 | New | History |
| IRONDisc Medicine, Inc. | COM | 486,957 | $30.9M | 3.0% | 00.0% | Unchanged | History |
| MLYSMineralys Therapeutics, Inc. | COM | 2,470,265 | $30.4M | 3.0% | 00.0% | Unchanged | History |
| TRMLTourmaline Bio, Inc. | COM | 1,477,593 | $30.0M | 2.9% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,063,000 | $28.8M | 2.8% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $27.6M | 2.7% | 00.0% | Unchanged | History |
| EYPTEyePoint, Inc. | COM NEW | 3,572,335 | $26.6M | 2.6% | +2,650,000+287.3% | Added | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 1,005,901 | $26.1M | 2.5% | +1,005,901 | New | History |
| THRDThird Harmonic Bio, Inc. | COM | 2,505,424 | $25.8M | 2.5% | +90,424+3.7% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 550,000 | $24.7M | 2.4% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,761,861 | $24.7M | 2.4% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $24.7M | 2.4% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $20.9M | 2.0% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 13,135,260 | $19.8M | 1.9% | +13,135,260 | New | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 4,643,812 | $17.6M | 1.7% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $14.6M | 1.4% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $12.4M | 1.2% | 00.0% | Unchanged | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $12.0M | 1.2% | 00.0% | Unchanged | History |
| KODKodiak Sciences Inc. | COM | 1,145,538 | $11.4M | 1.1% | +137,380+13.6% | Added | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $10.1M | 1.0% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 550,000 | $8.71M | 0.9% | −329,344−37.5% | Reduced | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,796,482 | $8.39M | 0.8% | −211,857−10.5% | Reduced | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $7.90M | 0.8% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 2,240,809 | $5.94M | 0.6% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM | 4,000,000 | $3.72M | 0.4% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $3.59M | 0.4% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $692.5K | 0.1% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 86,795 | $197.0K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q3 2024 (3)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| EWTXEdgewise Therapeutics, Inc. | COM | 2,112,984 | $56.4M | 4.8% | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 231,820 | $7.62M | 0.6% | History |
| ANTXAN2 Therapeutics, Inc. | COM | 1,555,118 | $1.66M | 0.1% | History |